Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy.
paper
Cited
Public
Unavailable
- Authors
- Sarginson, Jane E; Killen, Joel D; Lazzeroni, Laura C; Fortmann, Stephen P; Ryan, Heather S; Schatzberg, Alan F; Murphy, Greer M
- Year
- 2011
- Journal
- American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
- PMID
- 21268243
- DOI
- 10.1002/ajmg.b.31155
Stopping smoking is difficult even with treatment. Many patients prescribed pharmacologic treatments for smoking cessation experience side effects or lack of efficacy. We performed a pharmacogenetic study of the efficacy and tolerability of bupropion and transdermal nicotine (TN), two treatments for smoking cessation. Samples were drawn from two studies. In the first study (Maintenance 1, MT1), 301 smokers received bupropion plus TN for 11 weeks, followed by 14 weeks of placebo or bupropion. In the second study (MT2), 276 smokers received bupropion and TN for 8 weeks. We focused on eight SNPs in the 15q24 region, which contains the genes for the nicotinic cholinergic receptor subunits CHRNA5, CHRNA3, and CHRNB4, and has previously been implicated in nicotine addiction and smoking cessation. Analyses of baseline smoking quantity (SQ) identified an association between SQ and both the functional CHRNA5 SNP rs16969968 (D398N) and the CHRNA3 SNP rs1051730 (Y215Y) in a combined cohort containing MT1 and MT2. An association between SQ and ethnicity was also identified in the combined cohort. Pharmacogenetic analysis showed a significant association between rs8192475 (R37H) in CHRNA3 and both higher craving after quitting and increased withdrawal symptoms over time in MT2. Two markers for point prevalence abstinence, CHRNA5 SNP rs680244 and CHRNB4 SNP rs12914008, were also identified in MT2, with the strongest findings at week 52. These results provide further support for the role of the CHRNA5/A3/B4 subunits in determining number of cigarettes smoked and response to smoking cessation therapy.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| miR-135b: A Potential Biomarker for Pathological Diagnosis and Biological Therapy. | Yan D et al. | β | 2025 | β |
| Antidepressants for smoking cessation. | Hajizadeh A et al. | β | 2023 | β |
| A scoping review of smoking cessation pharmacogenetic studies to advance future research across racial, ethnic, and ancestral populations. | Prom-Wormley EC et al. | β | 2023 | β |
| CHRNA5-A3-B4 and DRD2 Genes and Smoking Cessation Throughout Adulthood: A Longitudinal Study of Women. | Jones SK et al. | β | 2023 | β |
| CHRNA5 gene variation affects the response of VTA dopaminergic neurons during chronic nicotine exposure and withdrawal. | Yang K et al. | β | 2023 | β |
| Genetic Associations with Smoking Relapse and Proportion of Follow-up in Smoking Relapse throughout Adulthood in Pre- and Postmenopausal Women. | Jones SK et al. | β | 2023 | β |
| Genomic medicine to reduce tobacco and related disorders: Translation to precision prevention and treatment. | Chen LS et al. | β | 2023 | β |
| Rare Missense Variants of the Human Ξ²4 Subunit Alter Nicotinic Ξ±3Ξ²4 Receptor Plasma Membrane Localisation. | Colombo SF et al. | β | 2023 | β |
| A systematic review of genetic variation within nicotinic acetylcholine receptor genes and cigarette smoking cessation. | Jones SK et al. | β | 2022 | β |
| Nicotine and opioid co-dependence: Findings from bench research to clinical trials. | Custodio L et al. | β | 2022 | β |
| The Promise of Polygenic Risk Prediction in Smoking Cessation: Evidence From Two Treatment Trials. | Bray M et al. | β | 2022 | β |
| Nicotinic acetylcholine gene cluster CHRNA5-A3-B4 variants influence smoking status in a Bangladeshi population. | Chaity NI et al. | β | 2021 | β |
| Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism. | Perez-Paramo YX et al. | β | 2021 | β |
| The Intergenerational Transmission of Developmental Nicotine Exposure-Induced Neurodevelopmental Disorder-Like Phenotypes is Modulated by the Chrna5 D397N Polymorphism in Adolescent Mice. | Buck JM et al. | β | 2021 | β |
| Ξ±5-nAChR and survivin: Two potential biological targets in lung adenocarcinoma. | Zhang Y et al. | β | 2021 | β |
| Antidepressants for smoking cessation. | Howes S et al. | β | 2020 | β |
| Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo-Controlled Trial. | Chen LS et al. | β | 2020 | β |
| Smoking cessation improves clinical outcome in severe mental disorders and is modulated by genetic variability at CHRNA5 gene. | Segura AG et al. | β | 2020 | β |
| Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline. | Tomaz PRX et al. | β | 2019 | β |
| Genetic variants in nicotinic receptors and smoking cessation in Parkinson's disease. | Chuang YH et al. | β | 2019 | β |
| Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial. | Roche DJO et al. | β | 2019 | β |
| Systematic Review of Polygenic Gene-Environment Interaction in Tobacco, Alcohol, and Cannabis Use. | Pasman JA et al. | β | 2019 | β |
| Cholinergic receptor nicotinic alpha 5 subunit polymorphisms are associated with smoking cessation success in women. | Tomaz PRX et al. | β | 2018 | β |
| From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation. | Salloum NC et al. | β | 2018 | β |
| Pathways to precision medicine in smoking cessation treatments. | Chen LS et al. | β | 2018 | β |
| Potential Micronutrients and Phytochemicals against the Pathogenesis of Chronic Obstructive Pulmonary Disease and Lung Cancer. | Zhai T et al. | β | 2018 | β |
| Preparing the Way: Exploiting Genomic Medicine to Stop Smoking. | Bierut LJ et al. | β | 2018 | β |
| The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings. | Saccone NL et al. | β | 2018 | β |
| Toward the implementation of genomic applications for smoking cessation and smoking-related diseases. | Ramsey AT et al. | β | 2018 | β |
| Examination of the Involvement of Cholinergic-Associated Genes in Nicotine Behaviors in European and African Americans. | Melroy-Greif WE et al. | β | 2017 | β |
| Pharmacogenetic Optimization of Smoking Cessation Treatment. | Chenoweth MJ et al. | β | 2017 | β |
| Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. | Schuit E et al. | β | 2017 | β |
| Pulmonary Effects of Maternal Smoking on the Fetus and Child: Effects on Lung Development, Respiratory Morbidities, and Life Long Lung Health. | McEvoy CT et al. | β | 2017 | β |
| Contribution of Variants in CHRNA5/A3/B4 Gene Cluster on Chromosome 15 to Tobacco Smoking: From Genetic Association to Mechanism. | Wen L et al. | β | 2016 | β |
| Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-Analysis. | Chen LS et al. | β | 2016 | β |
| Nicotinic acetylcholine receptors: upregulation, age-related effects and associations with drug use. | Melroy-Greif WE et al. | β | 2016 | β |
| Pleiotropic effects of Chr15q25 nicotinic gene cluster and the relationship between smoking, cognition and ADHD. | Schuch JB et al. | β | 2016 | β |
| The Role of Nicotine in the Effects of Maternal Smoking during Pregnancy on Lung Development and Childhood Respiratory Disease. Implications for Dangers of E-Cigarettes. | Spindel ER et al. | β | 2016 | β |
| A CHRNA5 Smoking Risk Variant Decreases the Aversive Effects of Nicotine in Humans. | Jensen KP et al. | β | 2015 | β |
| Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date. | Mamoun M et al. | β | 2015 | β |
| CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysis. | Chen LS et al. | β | 2015 | β |
| Effect of the rs1051730-rs16969968 variant and smoking cessation treatment: a meta-analysis. | Leung T et al. | β | 2015 | β |
| Gene network analysis shows immune-signaling and ERK1/2 as novel genetic markers for multiple addiction phenotypes: alcohol, smoking and opioid addiction. | Reyes-Gibby CC et al. | β | 2015 | β |
| Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. | Chen LS et al. | β | 2015 | β |
| Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking. | Tyndale RF et al. | β | 2015 | β |
| New mechanisms and perspectives in nicotine withdrawal. | Jackson KJ et al. | β | 2015 | β |
| Nicotine dependence in an isolated population of Kashubians from North Poland: a population survey. | Sieminska A et al. | β | 2015 | β |
| Nicotine withdrawal. | McLaughlin I et al. | β | 2015 | β |
| Response to Transdermal Selegiline Smoking Cessation Therapy and Markers in the 15q24 Chromosomal Region. | Sarginson JE et al. | β | 2015 | β |
| The value of control conditions for evaluating pharmacogenetic effects. | Chen LS et al. | β | 2015 | β |
| ADHD diagnosis may influence the association between polymorphisms in nicotinic acetylcholine receptor genes and tobacco smoking. | Polina ER et al. | β | 2014 | β |
| Antidepressants for smoking cessation. | Hughes JR et al. | β | 2014 | β |
| Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokers. | Zhu AZ et al. | β | 2014 | β |
| CHRNA5 variant predicts smoking cessation in patients with acute myocardial infarction. | Chen LS et al. | β | 2014 | β |
| Functional characterization improves associations between rare non-synonymous variants in CHRNB4 and smoking behavior. | Haller G et al. | β | 2014 | β |
| Habenular expression of rare missense variants of the Ξ²4 nicotinic receptor subunit alters nicotine consumption. | Slimak MA et al. | β | 2014 | β |
| Interplay of genetic risk (CHRNA5) and environmental risk (partner smoking) on cigarette smoking reduction. | Chen LS et al. | β | 2014 | β |
| Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome. | Leventhal AM et al. | β | 2014 | β |
| Nicotinic receptor modulation to treat alcohol and drug dependence. | Rahman S et al. | β | 2014 | β |
| Vitamin C supplementation for pregnant smoking women and pulmonary function in their newborn infants: a randomized clinical trial. | McEvoy CT et al. | β | 2014 | β |
| Biomarkers for smoking cessation. | Bough KJ et al. | β | 2013 | β |
| Genomics and personalized medicine: <i>CHRNA5-CHRNA3-CHRNB4</i> and smoking cessation treatment. | Chen LS et al. | β | 2013 | β |
| Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. | David SP et al. | β | 2013 | β |
| Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. | Bergen AW et al. | β | 2013 | β |
| Pharmacogenetic smoking cessation intervention in a health care setting: a pilot feasibility study. | McClure JB et al. | β | 2013 | β |
| Translational research in nicotine dependence. | Turner JR et al. | β | 2013 | β |
| From men to mice: CHRNA5/CHRNA3, smoking behavior and disease. | Ware JJ et al. | β | 2012 | β |
| Impact of human D398N single nucleotide polymorphism on intracellular calcium response mediated by Ξ±3Ξ²4Ξ±5 nicotinic acetylcholine receptors. | TammimΓ€ki A et al. | β | 2012 | β |
| Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. | Chen LS et al. | β | 2012 | β |
| Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. | Gold AB et al. | β | 2012 | β |
| Rare missense variants in CHRNB4 are associated with reduced risk of nicotine dependence. | Haller G et al. | β | 2012 | β |
| Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer. | Zienolddiny S et al. | β | 2012 | β |
| The CHRNA5-A3-B4 gene cluster in nicotine addiction. | Berrettini WH et al. | β | 2012 | β |